GSA Capital Partners LLP Makes New Investment in Viridian Therapeutics, Inc. $VRDN

GSA Capital Partners LLP bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 49,177 shares of the company’s stock, valued at approximately $903,000.

Other institutional investors also recently modified their holdings of the company. MetLife Investment Management LLC grew its stake in shares of Viridian Therapeutics by 0.8% in the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock valued at $1,369,000 after acquiring an additional 356 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Viridian Therapeutics by 0.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock worth $4,337,000 after purchasing an additional 380 shares in the last quarter. US Bancorp DE boosted its holdings in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares during the period. Bank of New York Mellon Corp boosted its holdings in Viridian Therapeutics by 0.3% in the 1st quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock valued at $4,235,000 after purchasing an additional 659 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after purchasing an additional 876 shares during the period.

Viridian Therapeutics Trading Up 3.6%

Shares of VRDN opened at $23.93 on Wednesday. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The business’s fifty day moving average is $19.31 and its 200-day moving average is $21.09. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of -7.10 and a beta of 0.91.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The business had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.06 million. Equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on VRDN. Royal Bank Of Canada raised their target price on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Weiss Ratings downgraded Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Evercore set a $26.00 price objective on Viridian Therapeutics in a research note on Friday, May 15th. Finally, Wedbush lifted their price objective on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.93.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.